Shares of Moderna jumped more than 8% in the extended session Tuesday as the pharmaceutical company said it has reached a ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Moderna (MRNA) stock has shed roughly 90% of its value since its 2021 peak.

Moderna shares are rising in Tuesday's after-hours session after the company announced it reached a settlement agreement.

This prompts a reassessment of the stock’s value to determine if this represents a genuine opportunity or a potential trap.

The company has had its ups -- the approval of its respiratory syncytial virus (RSV) vaccine back in 2024 -- and its downs -- the failure of its cytomegalovirus (CMV) vaccine candidate in a phase 3 ...

The Food and Drug Administration will review the investigational seasonal flu vaccine candidate after rejecting it earlier ...

Arbutus Biopharma (NASDAQ:ABUS) shares jumped 24% after hours Tuesday, while Roivant Sciences (NASDAQ:ROIV) rose 6.5% and ...

Moderna Inc MRNA shares are trading higher on Monday. Piper Sandler boosted its price target on the stock to $69 from $63 ...

Moderna (MRNA) stock fell 0.3% Friday despite beating Q4 revenue estimates at $678M and posting narrower loss of $2.11/share after FDA rejected flu vaccine review.

Moderna is a well-known biotech company from its pandemic success. Here's what investors should know about its growth story now.